Lanreotide Acetate (Lanreotide Acetate) Patent Expiration, LOE Window & CMS Spending

Lanreotide Acetate (Lanreotide Acetate) by Cipla: Off-Patent Genericized (AB Competition), 1 AB generics, $14.7M 2024 CMS Part D & Medicaid spend, and $6,693 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCipla
FDA Application & PathwayN215395 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$14.7M
2024 Medicare Part D Spend$8.7M
2024 Medicaid Spend$6.0M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($6,693 intro WAC)